Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022)

Historic Receivables - Net for Summit Therapeutics (SMMT) over the last 5 years, with Q4 2022 value amounting to $349000.0.

  • Summit Therapeutics' Receivables - Net fell 7616.12% to $349000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $349000.0, marking a year-over-year decrease of 7616.12%. This contributed to the annual value of $349000.0 for FY2022, which is 7616.12% down from last year.
  • Summit Therapeutics' Receivables - Net amounted to $349000.0 in Q4 2022, which was down 7616.12% from $140000.0 recorded in Q3 2022.
  • In the past 5 years, Summit Therapeutics' Receivables - Net registered a high of $17.3 million during Q1 2019, and its lowest value of $140000.0 during Q3 2022.
  • Moreover, its 4-year median value for Receivables - Net was $1.9 million (2021), whereas its average is $5.5 million.
  • As far as peak fluctuations go, Summit Therapeutics' Receivables - Net crashed by 9682.8% in 2020, and later soared by 34229.61% in 2021.
  • Quarter analysis of 4 years shows Summit Therapeutics' Receivables - Net stood at $10.4 million in 2019, then tumbled by 96.83% to $331000.0 in 2020, then skyrocketed by 342.3% to $1.5 million in 2021, then crashed by 76.16% to $349000.0 in 2022.
  • Its Receivables - Net stands at $349000.0 for Q4 2022, versus $140000.0 for Q3 2022 and $238000.0 for Q2 2022.